Apotex, Pfizer Make Peace On Generic Neurontin

Law360, New York (February 26, 2008, 12:00 AM EST) -- Apotex Corp. and Pfizer Inc. have settled all outstanding patent infringement and antitrust litigation over Pfizer's blockbuster epilepsy drug, Neurontin, which had earned the company more than $2 billion a year.

Having resolved almost a decade of dispute, Apotex is now free to continue marketing and selling the generic gabapentin capsules and tablets it first launched at risk in April 2005, an Apotex statement said Monday.

The terms and conditions of the settlement are confidential.

“We are pleased that we have been able to resolve this...
To view the full article, register now.